Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

LivePerson's Q1 Revenue Falls 12%

LivePerson’s first quarter showed a smaller loss on sharply lower revenue and much leaner operating costs.

Revenue fell to $56.956 million in the three months ended March 31, 2026, down from $64.700 million a year earlier, a decline of $7.744 million or about 12%.

Operating expenses dropped much faster than sales. Total costs, expenses and other came down to $58.707 million from $81.644 million, a reduction of $22.937 million. Within that total:

  • Cost of revenue fell to $15.525 million from $18.218 million
  • Sales and marketing dropped to $13.770 million from $23.485 million
  • General and administrative decreased to $12.120 million from $16.784 million
  • Product development declined to $12.180 million from $16.034 million
  • Depreciation and amortization eased to $5.112 million from $5.818 million
  • Restructuring costs were $0 in the latest quarter, versus $1.305 million a year ago

That cut the operating loss to $1.751 million, compared with $16.944 million in the prior-year quarter.

Below the operating line, results were weighed down by higher interest expense and weaker other income. Interest expense increased to $8.252 million from $7.478 million, while interest income fell to $503,000 from $1.457 million. Other income, net dropped to $998,000 from $8.487 million. As a result, total other expense swung to $6.751 million from $2.466 million of other income last year.

The company reported a net loss of $8.827 million, narrower than the $14.133 million loss in the same quarter last year. Loss per share improved as well:

  • Basic loss per share: $0.73, versus $2.32
  • Diluted loss per share: $0.73, versus $3.61

On the cash flow statement, operating cash generation turned positive. LivePerson produced $9.544 million of cash from operations, compared with a $3.096 million cash outflow a year earlier. That improvement came even though accounts receivable used $2.536 million of cash, and accounts payable, accrued expenses and other current liabilities used $604,000.

Investing cash outflow narrowed to $2.916 million from $4.145 million, helped by lower spending on property and equipment and software development, which fell to $2.644 million from $3.759 million. Purchases of intangible assets also declined to $272,000 from $386,000.

Cash and cash equivalents ended the quarter at $101.499 million, up from $95.004 million at December 31, 2025. Total assets rose slightly to $457.582 million from $454.667 million.

On the balance sheet, current liabilities climbed to $130.520 million from $122.569 million, driven by higher accrued expenses and deferred revenue. Accrued expenses and other current liabilities increased to $48.105 million from $38.700 million, and deferred revenue rose to $57.987 million from $54.295 million. Accounts payable fell sharply to $4.357 million from $9.522 million.

Debt was little changed at the current level, with current portion of long-term debt at $20.071 million and senior notes, net of current portion at $373.723 million. Total liabilities increased to $509.078 million from $499.162 million.

Stockholders’ deficit widened to $51.496 million from $44.495 million. The accumulated deficit deepened to $1.067 billion from $1.058 billion, while additional paid-in capital rose to $1.023 billion from $1.021 billion. Following these announcements, the company's shares moved 0.31%, and are now trading at a price of $8.155. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS